版本:
中国

BRIEF-Miragen Therapeutics receives EU orphan designation for MRG-106

May 24 Miragen Therapeutics Inc-

* Miragen Therapeutics receives EU orphan medicinal product designation for MRG-106 for the treatment of cutaneous t-cell lymphoma Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐